×
About 17,483 results

ACTIV-2: A Study for Outpatients With COVID-19
https://clinicaltrials.gov/ct2/show/NCT04518410

Oct 22nd, 2021 - This is a master protocol to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression. The study includes both infused and non-infused agents and is a randomized controlled platform that allows agents to be added and dropped during the course ...

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
https://clinicaltrials.gov/ct2/show/NCT04504032

Oct 22nd, 2021 - The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.

SARS-COV2 Pandemic Serosurvey in a Rare Disease Population
https://clinicaltrials.gov/ct2/show/NCT04609085

Oct 22nd, 2021 - It has been demonstrated that respiratory virus outbreaks and pandemics, such as influenza, SARS, MERS, and now the newly emerged SARS-COV2 virus, have a major impact on morbidity and mortality worldwide, as well as having devastating global economic and societal impact. During these outbreaks it is critical to gain a rapid understanding of the exposures and immunity in the general population. ...

Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
https://clinicaltrials.gov/ct2/show/NCT05007951

Oct 22nd, 2021 - The purpose of this study is to assess the immunogenicity and safety of SK SARS-CoV-2 recombinant nanoparticle vaccine adjuvanted with AS03 (GBP510) in adults aged 18 years and older. This study includes 2-dose schedule (28-day interval) of GBP510 and ChAdOx1-S. Participants are expected to participate for up to a maximum of approximately 13 months. A 12-month study follow-up after the 2nd vacc...

Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
https://clinicaltrials.gov/ct2/show/NCT05065827

Oct 22nd, 2021 - COVID-19 is a new disease significant morbidity and mortality which has reached pandemic status. Due to its highly contagious nature, is essential to characterise the disease pathology quickly and reliably. The lung changes that can be seen in patients with COVID-19 can precede clinical symptoms and are picked up on ultrasound more reliably than on conventional chest XR. In addition, ultrasound...

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19
https://clinicaltrials.gov/ct2/show/NCT05044780

Oct 22nd, 2021 - Background The new COVID19 pandemic has challenged the health system worldwide. Massive testing contact tracing and social distancing proved to be the most effective tools to fight the pandemic in absence of an effective vaccine. Despite the effort to develop rapid diagnostic testing, we still don t have an available large population screening modality. Hyperspectral analysis of sweat metabolit...

The Impact of Pituitary-thyroid and Pituitary-adrenal Axes Function on COVID-19 Clinical Course.
https://clinicaltrials.gov/ct2/show/NCT05070091

Oct 22nd, 2021 - The main focus of the study is the assessment of hormonal function in the course of COVID-19 infection with special regard for trends predicting clinical events defined as primary endpoints of the study.

A Post-Exposure Prophylaxis Study of PF-07321332/Ritonavir in Adult Household Contacts of an Individual With Symptomatic COVID-19
https://clinicaltrials.gov/ct2/show/NCT05047601

Oct 22nd, 2021 - The purpose of this study is to evaluate the efficacy and safety of PF-07321332/ritonavir as postexposure prophylaxis for adult household contacts of a patient with COVID-19

Developing and Testing a COVID-19 Vaccination Acceptance Intervention
https://clinicaltrials.gov/ct2/show/NCT05027464

Oct 22nd, 2021 - For Aim 1, the investigators will conduct a one-year cluster randomized controlled trial of a Vaccine Acceptance Intervention versus Usual Care with randomization at the level of VA Medical Center (VAMC). Usual Care will consist of all national and local initiatives to promote COVID-19 vaccine acceptance in Veterans such as vaccine mandates, mobile clinics, outreach calls, etc. The Implementati...

A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases
https://clinicaltrials.gov/ct2/show/NCT05035420

Oct 22nd, 2021 - The worldwide outbreak of novel Coronavirus Disease (COVID-19) has created a massive challenge for researchers and health professionals to increase testing capabilities and alleviate stress on the healthcare system. New tools are needed for diagnostic testing and monitoring under-treatment/observation patients who are infected by the virus. This challenge becomes more and more significant when ...

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)
https://clinicaltrials.gov/ct2/show/NCT05084911

Oct 22nd, 2021 - This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase III clinical trial to evaluate efficacy and safety of pyramax in mild to moderate COVID-19 patients.

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
https://clinicaltrials.gov/ct2/show/NCT05077267

Oct 22nd, 2021 - In a run in phase 6 adults (comprising of 3 subjects in each Group 1 and 2) will be vaccinated at 1 clinical trial site in a consecutive manner, with an at least 48 hours interval between the first and second subject of each group, then the second and third subject dosed on consecutive days, before opening up to full enrollment in Group 1 and 2. Safety assessments will be based on solicited and...

COVID-19 Immunity Assessment
https://clinicaltrials.gov/ct2/show/NCT05080231

Oct 22nd, 2021 - The DxTerity COVID-19 Immunity Assessment Collection Mailer Kit contains the DxCollect MicroCollection Device (MCD) Serology fingerstick blood collection device packaged as a home collection kit, designed for collection and shipment of fingerstick blood back to DxTerity CLIA (Clinical Laboratory Improvements Amendment) certified laboratory for testing. The clinical performance of the collection...

A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)
https://clinicaltrials.gov/ct2/show/NCT05074420

Oct 22nd, 2021 - The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected
https://clinicaltrials.gov/ct2/show/NCT05075070

Oct 22nd, 2021 - The subjects infected with HIV were recruited to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days . Blood samples will be collected 2 times: before the 1st dose of vaccinatioin and 28 days after the 2nd dose of vaccination. Any local or systemic adverse events that occurred within 21 days after vaccination will be recorded.

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD
https://clinicaltrials.gov/ct2/show/NCT05075057

Oct 22nd, 2021 - The subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease were recruited to receive three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively. Blood samples were collected before the first dose, 28 days after the second dose, before the third dose, 28 days after the third dose and 6 months after the third dose, respective...

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People Aged ≥18 Years With HIV Infected
https://clinicaltrials.gov/ct2/show/NCT05075044

Oct 22nd, 2021 - The subjects aged 18 years and above with HIV-infected were recruited to receive three doses of inactivated COVID-19 vaccine on day 0, day 21 and day 111, respectively. Blood samples were collected before the first dose, 28 days after the second dose, before the third dose, 28 days after the third dose and 6 months after the third dose, respectively. Any local or systemic adverse events that oc...

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Elderly People With Chronic Bronchitis and COPD
https://clinicaltrials.gov/ct2/show/NCT05075083

Oct 22nd, 2021 - The subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease were recruited to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days . Blood samples will be collected 2 times: before the 1st dose of vaccinatioin and 28 days after the 2nd dose of vaccination. Any local or systemic adverse events that occurred within ...

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
https://clinicaltrials.gov/ct2/show/NCT05088928

Oct 22nd, 2021 - There is an increased risk of Venous and Arterial thromboembolism in COVID-19 infection. The main reason being that the novel coronavirus SARS-CoV-2 induces hyperinflammation and subsequently immunothrombolism which is wide spread in the body3. The angiotensin converting enzyme 2 (ACE2) receptor, which is utilized by the virus to infect the host, is present throughout the human body organs and ...

Integrative Treatment Methods in COVID-19
https://clinicaltrials.gov/ct2/show/NCT05089578

Oct 22nd, 2021 - This study was a qualitative type of phenomenological study conducted to examine the use of integrative treatment methods by individuals undergoing Covid-19. The study was completed with 12 people. The data were collected between July and October 2021. The interviews lasted for an average of 25-30 minutes. The data collected with the semi-structured interview form were analyzed by descriptive c...